Clinical Trial Update: Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Tegeline (human immunoglobulin) for drug hypersensitivity syndrome (DRESS) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Drug Reaction with Eosinophilia and Systemic Symptoms

Drugs mentioned

• Tegeline (Intravenous immunoglobulin (IVIG))

Snippet

Sponsor: University Hospital, Rouen | Conditions: Drug Hypersensitivity | Phase 3 | Status: TERMINATED